Kast, R.E., Boockvar, J.A., Bruning, A., Capello, F., Chang, W.W., Cvek, B., Dou, Q.P., Duenas-Gonzalez, A., Efferth, T., Focosi, D., Ghaffari, S.H., Karpel-Massler, G., Ketola, K., Khoshnevisan, A., Keizman, D., Magne, N., Marosi, C., McDonald, K., Munoz, M., Paranjpe, A., Pourgholami, M.H., Sardi, I., Sella, A., Srivenugopal, K.S., Tucorri, M., Wang, W., Wirtz, C..R. and Halatsch, M.E. (2013) A Conceptually New Treatment Approach for Relapsed Glioblastoma; Coordinated Undermining of Survival Paths with Nine Repurposed Drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget, 4, 502-530.

has been cited by the following article:

• TITLE: Toxicological Evaluation of Disulfiram, Copper Gluconate and Disulfiram/Copper Gluconate Combination on Renal Function in Rodents

  AUTHORS: Udeme Owunari Georgewill, Iyeopu Minakiri Siminialayi, Atuboyedia Wolfe Obianime

  KEYWORDS: Disulfiram, Copper Gluconate, Renal Function

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.6 No.2, February 10, 2015

  ABSTRACT: This research work investigated and compared the chronic renal toxicological profile of disulfiram, copper gluconate and disulfiram/copper gluconate combination, in a 90-day time- and dose-dependent study in rodents. 88 rats weighing an average of 280 g divided into eleven groups consisting of 8 rats each were used for this experiment. The control groups received normal saline as placebo and 99.5% dimethyl sulfoxide (DMSO) (solvent control). Three oral doses (low, medium and high) of disulfiram (18.65 mg/kg, 37.3 mg/kg and 74.6 mg/kg), copper gluconate (3.75 mg/kg, 7.5 mg/kg and 15 mg/kg) and both drugs in combination were administered daily with those of the combination given 12 hours apart. Blood samples were collected via cardiac puncture in heparinised bottles and centrifuged, and the serum was decanted on 30, 45, 60 and 90 days for analysis. Renal function parameters—electrolytes (Na+, K+), urea and creatinine were evaluated. Results showed significant (p